MCID: ALP008
MIFTS: 56

Alopecia

Categories: Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Alopecia

MalaCards integrated aliases for Alopecia:

Name: Alopecia 11 58 75 28 5 43 14 71 75

Classifications:

Orphanet: 58  
Rare skin diseases


External Ids:

Disease Ontology 11 DOID:987
ICD9CM 34 704.0
MeSH 43 D000505
NCIt 49 C50575
SNOMED-CT 68 270504008
ICD10 31 L65.9
UMLS via Orphanet 72 C0002170
Orphanet 58 ORPHA79364
UMLS 71 C0002170

Summaries for Alopecia

Disease Ontology: 11 A hypotrichosis that is characterized by a loss of hair from the head or body.

MalaCards based summary: Alopecia is related to alopecia universalis congenita and alopecia-mental retardation syndrome 1, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia is SASH1 (SAM And SH3 Domain Containing 1), and among its related pathways/superpathways are Direct p53 effectors and Validated transcriptional targets of TAp63 isoforms. The drugs Acetylcysteine and Cetirizine have been mentioned in the context of this disorder. Affiliated tissues include Hair, and related phenotypes are growth/size/body region and endocrine/exocrine gland

Wikipedia 75 Alopecia: Hair loss, also known as alopecia or baldness, refers to a loss of hair from part of the head or body.... more...

Alopecia: Alopecia is a synonym for hair loss. In everyday use the term may refer specifically... more...

Related Diseases for Alopecia

Diseases in the Alopecia family:

Alopecia, Congenital

Diseases related to Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1340)
# Related Disease Score Top Affiliating Genes
1 alopecia universalis congenita 33.2 HR FOXN1 AIRE
2 alopecia-mental retardation syndrome 1 32.9 LSS AHSG
3 alopecia, neurologic defects, and endocrinopathy syndrome 32.9 RIN2 RBM28 DCAF17
4 woodhouse-sakati syndrome 32.4 RBM28 DCAF17
5 alopecia-mental retardation syndrome 32.1 MBTPS2 LSS AHSG
6 atrichia with papular lesions 32.0 HR FOXN1
7 hypotrichosis 31.7 LSS HR DCAF17 CLDN1
8 hypotrichosis 11 31.7 RIN2 RBM28 DCAF17
9 keratosis follicularis spinulosa decalvans, autosomal dominant 31.6 TP63 MBTPS2 KRT14
10 reticulate acropigmentation of kitamura 31.5 SASH1 KRT14
11 ankyloblepharon-ectodermal defects-cleft lip/palate 31.4 TP63 PERP
12 skin disease 31.1 VDR TP63 KRT14 DSP AIRE
13 hair disease 30.9 MBTPS2 KRT14 FOXN1 DSP DCAF17 AIRE
14 ectodermal dysplasia 30.7 TP63 KRT14 DSP AIRE
15 thymoma 30.6 TP63 DSP AIRE
16 spondylosis 30.1 VDR LSS
17 ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive 30.0 TP63 MBTPS2 KRT14
18 angular cheilitis 29.9 MBTPS2 AIRE
19 actinic keratosis 29.8 VDR TP63 KRT14
20 papilloma 29.7 TP63 ODC1 KRT14
21 epidermolysis bullosa simplex 2f, with mottled pigmentation 29.5 SASH1 KRT14 DSP
22 alopecia areata 11.9
23 alopecia, androgenetic, 1 11.8
24 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 11.7
25 palmoplantar keratoderma and congenital alopecia 2 11.6
26 palmoplantar keratoderma and congenital alopecia 1 11.6
27 androgenic alopecia 11.6
28 alopecia totalis 11.6
29 frontal fibrosing alopecia 11.6
30 central centrifugal cicatricial alopecia 11.5
31 gapo syndrome 11.5
32 alopecia-intellectual disability syndrome 4 11.5
33 mandibulofacial dysostosis with alopecia 11.5
34 cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 11.4
35 alopecia, psychomotor epilepsy, pyorrhea, and mental subnormality 11.4
36 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 11.4
37 alopecia-contractures-dwarfism-intellectual disability syndrome 11.4
38 alopecia-intellectual disability syndrome 2 11.4
39 polyposis, skin pigmentation, alopecia, and fingernail changes 11.4
40 bachmann-bupp syndrome 11.4
41 vitamin d-dependent rickets, type 2a 11.4
42 cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma 11.4
43 johnson neuroectodermal syndrome 11.4
44 growth restriction, hypoplastic kidneys, alopecia, and distinctive facies 11.4
45 crandall syndrome 11.4
46 alopecia-epilepsy-oligophrenia syndrome of moynahan 11.4
47 ichthyosis alopecia eclabion ectropion intellectual disability 11.3
48 follicular mucinosis 11.3
49 thumb deformity, alopecia, pigmentation anomaly 11.3
50 macs syndrome 11.3

Graphical network of the top 20 diseases related to Alopecia:



Diseases related to Alopecia

Symptoms & Phenotypes for Alopecia

UMLS symptoms related to Alopecia:


pruritus; exanthema

GenomeRNAi Phenotypes related to Alopecia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 AHSG AIRE AUTS2 CLDN1 DCAF17 DSP
2 no effect GR00402-S-2 10.18 AHSG AIRE AUTS2 CLDN1 DCAF17 FOXN1

MGI Mouse Phenotypes related to Alopecia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.25 AHSG AIRE AUTS2 CLDN1 DSP EDNRA
2 endocrine/exocrine gland MP:0005379 10.02 AIRE AUTS2 EDNRA FOXN1 HR KRT14
3 embryo MP:0005380 10.02 AUTS2 CLDN1 DSP EDNRA FOXN1 HR
4 neoplasm MP:0002006 10 AIRE AUTS2 FOXN1 HR KRT14 PERP
5 cellular MP:0005384 9.93 AUTS2 DCAF17 DSP EDNRA FOXN1 HR
6 hearing/vestibular/ear MP:0005377 9.91 AHSG EDNRA FOXN1 HR KRT14 VDR
7 mortality/aging MP:0010768 9.83 AIRE AUTS2 CLDN1 DSP EDNRA FOXN1
8 digestive/alimentary MP:0005381 9.8 AIRE DSP EDNRA HR KRT14 TP63
9 integument MP:0010771 9.28 CLDN1 DSP EDNRA FOXN1 HR KRT14

Drugs & Therapeutics for Alopecia

Drugs for Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 251)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
2
Cetirizine Approved Phase 4 83881-51-0 2678
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
7
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
8
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
9
Hydroxychloroquine Approved Phase 4 118-42-3 3652
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Apremilast Approved, Investigational Phase 4 608141-41-9 10151715 11561674
12
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
13
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
14
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
15
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
16
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 2791 5311051 32798
17
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
18
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
19
Cysteine Approved, Nutraceutical Phase 4 52-90-4 594 5862
20
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
21 N-monoacetylcystine Phase 4
22 Emollients Phase 4
23
Histamine phosphate Phase 4 51-74-1 134614
24 Histamine H1 Antagonists, Non-Sedating Phase 4
25 Histamine H1 Antagonists Phase 4
26 Histamine Antagonists Phase 4
27 Analgesics Phase 4
28 Anti-Infective Agents Phase 4
29 Antineoplastic Agents, Hormonal Phase 4
30 Neuroprotective Agents Phase 4
31
Methylprednisolone Acetate Phase 4 584547
32 Antiprotozoal Agents Phase 4
33 Antiparasitic Agents Phase 4
34 Antimalarials Phase 4
35 Anti-Arrhythmia Agents Phase 4
36 Sodium Channel Blockers Phase 4
37 Anesthetics, Local Phase 4
38 Phosphodiesterase 4 Inhibitors Phase 4
39 Anti-Inflammatory Agents, Non-Steroidal Phase 4
40 Analgesics, Non-Narcotic Phase 4
41 Adjuvants, Immunologic Phase 4
42 interferons Phase 4
43 Antibiotics, Antitubercular Phase 4
44 Anti-Bacterial Agents Phase 4
45 Anti-Asthmatic Agents Phase 4
46 Betamethasone-17,21-dipropionate Phase 4
47
Betamethasone Valerate Phase 4 2152-44-5
48
Betamethasone sodium phosphate Phase 4
49
Betamethasone benzoate Phase 4
50 Respiratory System Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 401)
# Name Status NCT ID Phase Drugs
1 Does Carboxytherapy Play a Role in Alopecia Areata Either Solely or in Combination? Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids Unknown status NCT04228029 Phase 4 Intralesional Steroid Injection
2 Efficacy and Tolerability of N-Acetyl- Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men Unknown status NCT04209803 Phase 4 Minoxidil 5% topically and oral NAC 600 mg
3 Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Unknown status NCT04293822 Phase 4 Cetirizine;Minoxidil
4 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
5 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Unknown status NCT03388840 Phase 4
6 Efficacy of Fractional CO2 Laser Alone and as Transepidermal Drug Delivery for Different Modalities of Treatment in Alopecia Areata Unknown status NCT04003376 Phase 4 Triamcinolone Acetonide 10mg/mL;vitamin D solution
7 Modified SALT Score for Assessment of Alopecia Areata Unknown status NCT04412148 Phase 4 Triamcinolone Acetonide
8 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
9 Open Label Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Unknown status NCT03422640 Phase 4 Apremilast
10 Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation Unknown status NCT03473600 Phase 4 Triamcinolone acetonide injection
11 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate
12 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
13 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Completed NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
14 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Completed NCT03800979 Phase 4 Tofacitinib
15 Minoxidil in Treatment of Androgenetic Alopecia Completed NCT04090801 Phase 4 Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone
16 Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin Completed NCT00176969 Phase 4 Capsaicin
17 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
18 Phenotype and Cytokine Production Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Aldara 5% Cream Using Flow Cytometry Completed NCT00176943 Phase 4 Aldara Cream 5%
19 Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
20 An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Completed NCT03521687 Phase 4 Apremilast
21 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
22 A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
23 Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study Recruiting NCT04207931 Phase 4 Topical steroid class I-II;Triamcinolone Acetonide;Doxycyline;Minoxidil
24 Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata: a Pilot Study of Patient Tolerability Recruiting NCT05278858 Phase 4
25 The Use of Hydradermabrasion in the Scalp to Improve Scalp Health and Improve Outcomes in Androgenetic Alopecia Recruiting NCT05426629 Phase 4
26 The Efficacy of Combining 308 Nm-Excimer Light and Topical Steroid in the Treatment of Alopecia Areata Not yet recruiting NCT04793945 Phase 4
27 A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata Terminated NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
28 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
29 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
30 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
31 TREg Activation in the Treatment of the PELADE (Alopecia Areata). Double Blind Randomized Placebo Controlled Comparative Study Using Low Doses of IL2 Completed NCT02557074 Phase 3 IL2;placebo
32 A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS Completed NCT03732807 Phase 2, Phase 3 PF-06651600 Induction Dose;PF-06651600 Maintenance Dose #1;PF-06651600 Maintenance Dose #2;PF-06651600 Maintenance Dose #3;Placebo
33 RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHOTREXATE AT PATIENTS AFFECTED BY GRAVE PELADE (METHOTREXATE VERSUS PLACEBO WITH SECONDARY TREATMENT BY METHOTREXATE and PREDNISONE) Completed NCT02037191 Phase 3 Methotrexate;Placebo
34 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
35 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia Completed NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical vehicle solution
36 Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study Completed NCT03753113 Phase 3 Topical Herbal Solution;Topical Minoxidil 5%
37 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
38 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
39 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
40 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
41 A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males Completed NCT00151515 Phase 3 minoxidil
42 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
43 A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata Completed NCT04797650 Phase 3 CTP-543, 8 mg BID;CTP-543, 12 mg BID;Placebo, BID
44 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
45 Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia: A Randomized, Double-blind Clinical Trial Completed NCT05296863 Phase 3
46 A Two Stage Phase II Randomized Bilateral Comparison of Topical Targretin® Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
47 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
48 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
49 A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
50 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion

Search NIH Clinical Center for Alopecia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


D-BIOTIN
Finasteride
Minoxidil

Cochrane evidence based reviews: alopecia

Genetic Tests for Alopecia

Genetic tests related to Alopecia:

# Genetic test Affiliating Genes
1 Alopecia 28

Anatomical Context for Alopecia

Organs/tissues related to Alopecia:

MalaCards : Skin, Breast, T Cells, Brain, Lung, Prostate, Bone Marrow
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alopecia:
# Tissue Anatomical CompartmentCell Relevance
1 Hair Hair Follicle Fetal Hair Placode Cells Affected by disease
2 Hair Hair Follicle Fetal Matrix Cells Affected by disease
3 Hair Dermal Papilla Guard Dermal Papilla Cells Affected by disease
4 Hair Hair Follicle Primary Hair Placode Cells Affected by disease

Publications for Alopecia

Articles related to Alopecia:

(show top 50) (show all 19638)
# Title Authors PMID Year
1
Clinical manifestations of alopecia in autoimmune blistering diseases: A cross-sectional study. 62
36387063 2023
2
A simple solution to create a custom scalp-sparing helmet to prevent alopecia in patients undergoing total skin electron beam therapy for cutaneous T cell lymphoma. 62
36388245 2023
3
Evaluation of chemotherapy-induced cutaneous side effects in cancer patients. 62
35867950 2022
4
Trichoscopic diagnosis of structural hair defects in a clinical setting: A Cross-sectional analytical study. 62
36470219 2022
5
Response to Weinstein's "Reply of Increased risk of vitamin D deficiency and insufficiency in Black patients with central centrifugal cicatricial alopecia." 62
35973596 2022
6
Reply to Increased risk of vitamin D deficiency and insufficiency in Black patients with central centrifugal cicatricial alopecia. 62
35964829 2022
7
A Rare Case of Protein-Losing Enteropathy, Alopecia, Hyperpigmentation and Dystrophy of the Nails: A Case Report. 62
35876739 2022
8
IL-17 Expression in the Perifollicular Fibrosis in Biopsies From Lichen Planopilaris. 62
36197049 2022
9
Alopecia areata after severe allergic contact dermatitis to a permanent hair dye. 62
35984243 2022
10
Ox40-Cre-mediated deletion of BRD4 reveals an unexpected phenotype of hair follicle stem cells in alopecia. 62
36256455 2022
11
Cells, growth factors and biomaterials used in tissue engineering for hair follicles regeneration. 62
36475027 2022
12
Preparation and optimization of aloe ferox gel loaded with Finasteride-Oregano oil nanocubosomes for treatment of alopecia. 62
35019794 2022
13
Merkel cell number and distribution, and CD200 expression in patients with lichen planopilaris and discoid lupus erythematosus. 62
36445269 2022
14
Hair Follicle Melanocytes Initiate Autoimmunity in Alopecia Areata: a Trigger Point. 62
36121544 2022
15
Using artificial intelligence to analyze publicly available social media posts to understand patient perspectives toward specific treatments of alopecia areata. 62
36237847 2022
16
Pediatric pulse dose corticosteroid therapy dosing and administration in the treatment of alopecia areata: A review of literature. 62
36461625 2022
17
Oral tofacitinib for successful treatment of refractory alopecia areata in preschool children. 62
35876014 2022
18
Downregulation of pathogenic MICA-NKG2D interactions as a novel strategy in alopecia areata management: a new rationale for adjunct statin therapy? 62
35841295 2022
19
Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients. 62
36045513 2022
20
Are Sunscreen Particles Involved in Frontal Fibrosing Alopecia?-A TEM-EDXS Analysis on Formalin-Fixed Paraffin-Embedded Alopecia Biopsies (Pilot Study). 62
36197059 2022
21
Psychosocial burden of frontal fibrosing alopecia: a qualitative interview study. 62
35867867 2022
22
Exploring potential decreasing age of patients with frontal fibrosing alopecia. 62
36034744 2022
23
The efficacy of subcutaneous slow-release melatonin implants in the prevention of canine flank alopecia recurrence is uncertain: A double-blind, randomized, placebo-controlled study. 62
36106629 2022
24
Response to the study by Collins et al "Retrospective review of adverse events associated with oral hydroxychloroquine use in patients with cicatricial alopecia." 62
36075283 2022
25
Eyebrow hair loss as a prognostic factor for frontal fibrosing alopecia. 62
36089939 2022
26
The number of mitochondrial DNA mutations as a genetic feature for hair cycle arrest (alopecia X) in Pomeranian dogs. 62
36000586 2022
27
Reply to "Response to Collins et al.'s 'Retrospective review of adverse events associated with oral hydroxychloroquine use in patients with cicatricial alopecia'". 62
36075279 2022
28
Evaluation of the CNC® prosthetic system in recurrent breast cancer patients with chemotherapy-induced alopecia: a pilot study. 62
36463143 2022
29
Repurposing levocetirizine hydrochloride loaded into cationic ceramide/phospholipid composite (CCPCs) for management of alopecia: central composite design optimization, in- silico and in-vivo studies. 62
36047012 2022
30
Supplementation and hair growth: A retrospective chart review of patients with alopecia and laboratory abnormalities. 62
36147213 2022
31
An Analysis of Alopecia Related Content on Instagram and TikTok. 62
36468968 2022
32
Scarring alopecia and scalp pruritus. 62
36457937 2022
33
Shared decision making for patients with breast and gynecologic malignancies undergoing chemotherapy associated with persistent alopecia. 62
36388759 2022
34
Frontal fibrosing alopecia sparing a dermal melanocytic nevus: a report of two cases of Renbök phenomenon. 62
35842928 2022
35
Therapeutic potential of adipose tissue-derivatives in modern dermatology. 62
35102608 2022
36
Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases. 62
36346551 2022
37
New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology. 62
35986858 2022
38
Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy. 62
36468955 2022
39
Pediatric Game Changers∗: Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. 62
35933066 2022
40
Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors. 62
36335798 2022
41
When Recurrent Strokes, Back Pain, and Alopecia Constitute a Hereditary Cause of Small-Vessel Disease, CARASIL in an Arabic Woman. 62
36455066 2022
42
JAK: Not Just Another Kinase. 62
36252553 2022
43
Evolving utility of apremilast in dermatological disorders for off-label indications. 62
35974705 2022
44
Treatment Patterns and Treatment Satisfaction Among Adults with Alopecia Areata in the United States. 62
36223027 2022
45
A Comprehensive Review of Microneedling as a Potential Treatment Option for Androgenetic Alopecia. 62
35930041 2022
46
Transcriptomic analysis identifies regulators of the Wnt signalling and hypoxia-inducible factor pathways as possible mediators of androgenetic alopecia. 62
36199226 2022
47
Dendrobium officinale Polysaccharide (DOP) Promotes Hair Regrowth in Testosterone-Induced Bald Mice. 62
36470987 2022
48
Telemedical care of men with androgenetic alopecia demonstrates improved access to care and patient benefit. 62
35841293 2022
49
Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/β-catenin signalling pathways. 62
35862273 2022
50
Microneedle mediated transdermal delivery of β-sitosterol loaded nanostructured lipid nanoparticles for androgenic alopecia. 62
36110028 2022

Variations for Alopecia

ClinVar genetic disease variations for Alopecia:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SASH1 NM_015278.5(SASH1):c.1849G>A (p.Glu617Lys) SNV Likely Pathogenic
156162 rs587781245 GRCh37: 6:148855021-148855021
GRCh38: 6:148533885-148533885
2 overlap with 9 genes GRCh37/hg19 18p11.32-11.31(chr18:1345040-3479168) CN LOSS Uncertain Significance
523239 GRCh37: 18:1345040-3479168
GRCh38:

Expression for Alopecia

Search GEO for disease gene expression data for Alopecia.

Pathways for Alopecia

Pathways related to Alopecia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.54 VDR TP63 PERP
2 11.06 VDR TP63 PERP
3 10.86 TP63 PERP FOXN1
4 10.6 VDR TP63 PERP KRT14

GO Terms for Alopecia

Biological processes related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 epidermis development GO:0008544 9.7 TP63 KRT14 FOXN1 DSP
2 desmosome organization GO:0002934 9.56 PERP DSP
3 thymus epithelium morphogenesis GO:0097536 9.26 FOXN1 AIRE
4 keratinocyte differentiation GO:0030216 9.23 TP63 KRT14 FOXN1 DSP

Sources for Alopecia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....